Cargando…
Imatinib augments standard malaria combination therapy without added toxicity
To egress from its erythrocyte host, the malaria parasite, Plasmodium falciparum, must destabilize the erythrocyte membrane by activating an erythrocyte tyrosine kinase. Because imatinib inhibits erythrocyte tyrosine kinases and because imatinib has a good safety profile, we elected to determine whe...
Autores principales: | Chien, Huynh Dinh, Pantaleo, Antonella, Kesely, Kristina R., Noomuna, Panae, Putt, Karson S., Tuan, Tran Anh, Low, Philip S., Turrini, Francesco M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404470/ https://www.ncbi.nlm.nih.gov/pubmed/34436509 http://dx.doi.org/10.1084/jem.20210724 |
Ejemplares similares
-
Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia
por: Kesely, Kristina, et al.
Publicado: (2020) -
Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia
por: Kesely, Kristina R., et al.
Publicado: (2016) -
Induction of high tolerance to artemisinin by sub-lethal administration: A new in vitro model of P. falciparum
por: De Lucia, Serena, et al.
Publicado: (2018) -
Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies
por: Luo, Weichuan, et al.
Publicado: (2022) -
Activation of a dendritic cell–T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells
por: Perreau, Matthieu, et al.
Publicado: (2008)